Skip to main content Back to Top
Advertisement

6/26/2020

Sodium Polystyrene Sulfonate Oral or Rectal Suspension

Products Affected - Description

    • SPS Suspension, CMP Pharma, 15 gram/60 mL, 120 mL contains sorbitol bottle, NDC 46287-0006-04
    • SPS Suspension, CMP Pharma, 15 gram/60 mL, 473 mL contains sorbitol bottle, NDC 46287-0006-01
    • SPS Suspension, CMP Pharma, 15 gram/60 mL, 60 mL contains sorbitol bottle, 10 count, NDC 46287-0006-60
    • Sodium Polystyrene Sulfonate suspension, Hikma, 15 gram/60 mL, 120 mL bottle, NDC 00054-0379-50
    • Sodium Polystyrene Sulfonate suspension, Hikma, 15 gram/60 mL, 500 mL bottle, NDC 00054-0379-63 - discontinued
    • Sodium Polystyrene Sulfonate suspension, Hikma, 15 gram/60 mL, 60 mL bottle, 10 count, NDC 00054-0379-51

Reason for the Shortage

    • CMP Pharma reports that increased demand has led to a shortage of raw material required to manufacture the products. They are using available powder to manufacture the suspension.
    • Perrigo has temporarily discontinued their Kionex suspension and sodium polystyrene sulfonate (sorbitol-free) suspension. They cannot estimate when these products will be manufactured again.
    • Hikma is not currently marketing sodium polystyrene sulfonate suspension.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • CMP Pharma has SPS Suspension on allocation and the company is shipping supplies regularly.

Implications for Patient Care

    • Other potassium binders include patiromer (Veltassa; Relypsa) and sodium zirconium cyclosilicate (Lokelma; AstraZeneca).

Updated

Updated June 26, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created June 4, 2018 by Leslie Jensen, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.